Conexeu Sciences Inc. (CNXU)
NASDAQ: CNXU · Real-Time Price · USD
10.96
+0.74 (7.24%)
At close: Jun 26, 2026, 4:00 PM EDT
11.38
+0.42 (3.83%)
After-hours: Jun 26, 2026, 7:58 PM EDT

Company Description

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair.

The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration.

Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis.

The company’s solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications.

The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair.

The company was founded in 2022 and is based in Reno, Nevada.

Conexeu Sciences Inc.
Conexeu Sciences logo
Country United States
Founded 2022
Industry Biotechnology
Sector Healthcare
CEO Miles Harrison

Contact Details

Address:
50 West Liberty Street, Suite 880
Reno, Nevada 89501
United States
Phone (604) 315-4722
Website conexeu.com

Stock Details

Ticker Symbol CNXU
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year November - October
Reporting Currency USD
CIK Code 0002066836
CUSIP Number 20715F100
ISIN Number US20715F1003
SIC Code 3842

Key Executives

Name Position
Miles D. Harrison President, Chief Executive Officer and Director
Dr. Claudia Chavez-Munoz M.D., Ph.D. Founder and Chief Scientific Officer
Stephen D. Inouye Chief Financial Officer, Corporate Secretary and Treasurer
Dr. Brian K. Pilcher Ph.D. Chief Medical Officer
Sonia Thomas M.B.A. Head of Strategy and Transformation
JR Falconne Head of Business Development and Licensing

Latest SEC Filings

Date Type Title
Jun 16, 2026 424B3 Prospectus
Jun 15, 2026 10-Q Quarterly Report
Jun 12, 2026 D/A Filing
Jun 10, 2026 D Notice of Exempt Offering of Securities
Jun 9, 2026 8-K Current Report
May 21, 2026 D Notice of Exempt Offering of Securities
May 21, 2026 D Notice of Exempt Offering of Securities
May 15, 2026 424B3 Prospectus
May 15, 2026 8-K Current Report
May 15, 2026 424B3 Prospectus